Display options
Share it on

Int J Neonatal Screen. 2021 Feb 13;7(1). doi: 10.3390/ijns7010011.

Newborn Screening for CAH-Challenges and Opportunities.

International journal of neonatal screening

Natasha L Heather, Anna Nordenstrom

Affiliations

  1. National Newborn Metabolic Screening programme, Specialist Chemical Pathology, LabPlus, Auckland City Hospital, Auckland 1023, New Zealand.
  2. Clinical Research Unit, Liggins Institute, University of Auckland, Auckland 1010, New Zealand.
  3. Centre for Inherited Metabolic Diseases, Karolinska University Hospital, SE-171 76 Stockholm, Sweden.
  4. Department of Women's and Children's Health, Karolinska Institutet, SE-171 76 Stockholm, Sweden.
  5. Pediatric Endocrinology Unit, Astrid Lindgren´s Children's Hospital, Karolinska University Hospital, SE-171 76 Stockholm, Sweden.

PMID: 33668620 PMCID: PMC8006248 DOI: 10.3390/ijns7010011

Abstract

Newborn screening for congenital adrenal hyperplasia (CAH) using 17-hydroxyprogesterone (17-OHP) as an indicator of disease was first introduced in the 1970s [...].

References

  1. Int J Neonatal Screen. 2020 Sep 25;6(4): - PubMed
  2. Int J Neonatal Screen. 2020 Aug 12;6(3):63 - PubMed
  3. Int J Neonatal Screen. 2020 Jun;6(2): - PubMed
  4. Int J Neonatal Screen. 2020 Aug 27;6(3): - PubMed
  5. Int J Neonatal Screen. 2020 Aug 14;6(3): - PubMed
  6. Int J Neonatal Screen. 2020 Aug 26;6(3):68 - PubMed
  7. Int J Neonatal Screen. 2020 Aug 28;6(3): - PubMed
  8. Int J Neonatal Screen. 2020 Aug 23;6(3):67 - PubMed
  9. J Clin Endocrinol Metab. 1977 Nov;45(5):1003-8 - PubMed
  10. Int J Neonatal Screen. 2020 Jan 28;6(1):6 - PubMed

Publication Types